8-K: BiomX Board Sees Director Resignations, Appoints Liat Bidas

BiomX Inc. announced the resignations of two directors and the appointment of Liat Bidas to its Board of Directors.

Summary

• Jonathan Leff resigned from the Board of Directors of BiomX Inc. on February 9, 2026, for personal reasons, effective immediately.
• Jesse Goodman resigned from the Board of Directors of BiomX Inc. on February 11, 2026, for personal reasons, effective immediately.
• Neither Mr. Leff nor Mr. Goodman reported any disagreement with the Company regarding its operations, policies, or practices.
• The Company is actively seeking new candidates to fill the resulting vacancies on the Board.
• On February 13, 2026, Liat Bidas was appointed as a Class II Director, with her term expiring at the Company's annual meeting of stockholders in 2028.
• Ms. Bidas is a Managing Partner at UpStream Capital Group since 2014, focusing on financial and real estate investments, and providing advisory services and merger proposals.
• Since 2022, Ms. Bidas has served as a director of BioView, a publicly traded medical diagnostic device company, and has been involved in its business development since 2023.
• Her prior experience includes serving as Chairperson of the Board for Dirom Construction Investments and Development Company Ltd. (2014-2015) and Inventech Central Hotels (2014-2015), and working in investment banking with Top Alpha Capital (2011-2014).
• Ms. Bidas also has a long tenure with Active Optic Systems Ltd. since 1999, serving on its board of directors since 2019.
• She holds undergraduate studies in psychology, criminology, and sociology from Bar-Ilan University, and completed additional financial studies including risk management, financial statements, corporate governance, and a directors course.
• The Board concluded that Ms. Bidas is qualified and independent under NYSE American LLC rules.
• Ms. Bidas will receive standard director compensation, with annual cash fees prorated, and will enter into a standard indemnification agreement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. While two directors departed, the prompt appointment of an experienced director like Ms. Bidas helps maintain board strength and demonstrates proactive governance.

Positives

• The appointment of Liat Bidas brings extensive experience in financial investments, corporate governance, and medical device business development to the Board.
• The Board has promptly filled one of the two vacancies, demonstrating proactive corporate governance.
• No disagreements were reported by the departing directors, suggesting their resignations were for personal reasons rather than internal disputes.

Negatives

• Two directors resigned from the Board, creating vacancies that need to be filled.
• The Company still needs to find a candidate to fill the remaining vacancy on the Board.

Risks

• Potential for disruption to board continuity due to multiple director changes.
• The ongoing search for additional board candidates could take time, potentially leaving a vacancy for a period.

Future Outlook

The Company is actively seeking new candidates to fill the remaining vacancy on the Board of Directors.

Industry Context

StockSavvy.ai notes that board refreshment is a common practice, and bringing in directors with diverse financial and governance backgrounds, like Ms. Bidas, can strengthen oversight and strategic direction, especially for biotech companies navigating complex markets. The prompt filling of one vacancy demonstrates a commitment to maintaining board functionality.

Comparison to Industry Standards

• StockSavvy.ai observes that the appointment of a director with extensive experience in financial investments, real estate, and medical diagnostic devices, as seen with Ms. Bidas's background at UpStream Capital Group and BioView, aligns with industry best practices for strengthening board expertise. Many biotech companies seek directors with a blend of financial acumen and relevant industry experience to guide growth and navigate regulatory landscapes.
• The proactive approach to filling board vacancies, even with multiple departures, is consistent with strong corporate governance standards seen in leading public companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from the addition of an experienced and independent director, which can enhance board oversight and strategic guidance. The proactive management of board vacancies maintains governance stability.
• Employees: No direct impact mentioned, but stable corporate governance generally supports a stable work environment.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The Company will continue to actively seek new candidates to fill the remaining vacancy on the Board of Directors.

Key Dates

Recommendation

The filing primarily concerns routine corporate governance changes, specifically director resignations and an appointment. While the addition of an experienced director like Liat Bidas is a positive step for board strength, the information presented does not provide new financial or operational data that would warrant a change in investment recommendation. Investors should hold and monitor future operational and financial reports.

Keywords

BiomX, Board of Directors, Director Appointment, Corporate Governance, Liat Bidas, Resignation, PHGE, SEC 8-K, Biotechnology